


U.S.S.N. 09/247,406  
Filed: February 10, 1999  
**AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT**

in the Office Action. For these additional reasons, applicant respectfully requests joinder and examination of Groups I, VII, IX, and X, claims 1-28, 46-53, and 61-88.

4. In regard to designation of generic claims, applicants refer to MPEP § 806.04(e) which states that "[c]laims may be restricted to a single disclosed embodiment (i.e. a single species, and thus be designated *a specific or species claim*), or a claim may include two or more of the disclosed embodiment...(and thus be designated *a generic or genus claim*)" (emphasis in original). In this regard, applicants note that only claim 15 is limited to the elected species, immunostimulatory activity. Thus, only claim 15 is a specific claim defined above. Accordingly, applicants note that, with respect to the elected species, immunostimulatory activity, claims 1-14 and 16-88 are generic.

Favorable consideration of claims 1-28, 46-53, and 61-88 is earnestly solicited.

Respectfully submitted,

  
\_\_\_\_\_  
Robert A. Hodges  
Reg. No. 41,074


Date: March 23, 2000

ARNALL, GOLDEN & GREGORY, LLP  
2800 One Atlantic Center  
1201 West Peachtree Street  
Atlanta, Georgia 30309-3450  
(404) 873-8796  
(404) 873-8797 (fax)

U.S.S.N. 09/247,406  
Filed: February 10, 1999  
AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

**CERTIFICATE OF FACSIMILE TRANSMISSION**

I hereby certify that the enclosed Response to Restriction Requirement and all documents shown as being attached is being facsimile transmitted to the T. Wessendorf of the U.S. Patent and Trademark Office at (703) 305-3704 on the date shown below.

  
Teresa R. Spratt

Date: March 23, 2000